Gilead on the Hunt for Acquisitions

Source: Financial Times

Dec 08, 2015

Cash-rich Gilead is exploring potential acquisition targets, in search of its next blockbuster, reports Financial Times.

Gilead is specifically targeting companies offering drugs that have already had successful early-stage trials. Norbert Bischofberger, Gilead's executive vice-president of research and development, told FT in an interview, “We have our eye on the external world — we have incredible cash flows and we are looking for opportunities.”

Harvoni, approved in October 2014 and Sovaldi, approved in December 2013 bear the bulk of the credit for the biotech's $27 billion in Hep C revenue.

Sovaldi's $1000 per pill pricetag has Gilead under fire in the war against high drug pricing. A recent U.S. Senate investigation into pricing of blockbuster medicines found that U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead's new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the disease.

Read the FT article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments